Introduction
The mammalian intestine continuously comes in contat with prokaryotes, which are indispensable partners for developing intestinal tissue and maintaining its homeostasis.
The International Human Microbiome Project (1) (2) has provided a tremendous amount of information on commensal bacteria and has ushered in a new era for the field of gastroenterology. It is clear that more than 2,000 species of commensal bacterial organisms exist in our bodies, and the majority is located in the gut, but most of these bacteria are not pathogens (3) . Recently, new ribosomal RNA-and whole genome-based technologies have highlighted that the populations of microbial species differ between individuals, regions of the gut axis (4) , and different mucosal layers at a single anatomical site, thus illustrating the diverse and complicated role of "the partner" in our biological activities (5) (6) .
Probiotics, which are defined as "live microorganisms which confer a health benefit on the host, when administered in adequate amounts" (7) , have potential effects for human health as well as the treatment of intestinal disorders. Indeed, many etiological studies have proposed the beneficial effects of probiotics since 100 years ago (8) (9) (10) . Several recent meta-analyses and systematic reviews suggest that probiotics are potentially useful preventive or therapeutic strategies for multiple gastrointestinal 6 diseases, while the data from these studies were based on various subjects using different genera, species, strains, and doses of probiotics (11) (12) (13) (14) (15) (16) (17) (18) . However, data from probiotic treatments remain preliminary thus far, and are influenced by the diversity of the microbiota, diets, and genetic backgrounds of the individual subjects. It is crucial to elucidate the mechanisms of certain probiotic functions. Early mechanistic investigations involved the remodeling of microbial communities to suppress the growth and activity of pathogens, particularly in acute infections. Subsequently, probiotics were found to cause various effects, including the upregulation of anti-inflammatory factors, immunomodulation via the suppression of pro-inflammatory mediators, enhanced immunity, epithelial cell differentiation and proliferation, and promotion of intestinal barrier function. In the present review, the clinical and physiological effects of probiotics and novel perspectives in the mechanistic studies of the probiotic effects are discussed.
Clinical benefits of probiotics
There is increasing evidence that probiotics are required for the development of a 
1) Intestinal development
It is known that the intestinal microbiota are important for the development of the normal gut, particularly in maintaining normal immunological reactions and cytoprotective responses, and also in regulating apoptosis (19) (20) (21) . Indeed, LGG decreases chemically induced apoptosis and increases the expression of genes involved in cytoprotective responses in the developing mouse small intestine (22) . The administration of Lactobacillus casei DN-114001 appears to ameliorate the gut immune response through the stimulation of macrophages and dendritic cells (23). These studies demonstrate that the probiotics may thus play a significant role in intestinal development.
2) Nutrition
Intestinal microbiota are heavily involved in the regulation of human and other host nutritional status, including the promotion of polysaccharide digestion and nutrient uptake and the regulation of the energy balance by cooperation with intestinal epithelial cells (24) (25) . Intestinal microbiota regulate energy balance by using and 8 storing the calories harvested from the host's diet (26) (27) . Furthermore, a recent study has shown the deviations from a gut core microbiome, which shares the genes involved in various metabolic functions, to be associated with aberrant physiological states, such as obesity (28) . Supportive evidence concerning the probiotic effects on the prevention and treatment of obesity has been recently addressed by clinical trials (29) (30).
3) Intestinal disorders A) Infectious diseases
There are many studies which reveal the therapeutic effects of probiotic treatment for several types of the infectious enteritis (31) (32). Travelers' diarrhea is one of the common diseases among travelers to foreign countries, particularly in Africa and Southeast Asia. From the data of more than 10 randomized controlled studies, probiotic treatments have been shown to be safe and effective for the prevention of travelers' diarrhea (33) (34). However, this effect appears to be dependent on the population of each study, the type of probiotics used, the duration of treatment, the trip destination, and the compliance with treatment. Otherwise, the therapeutic and preventive effects of probiotics such as VSL#3, a mixture of 8 probiotic bacteria, and Lactobacillus rhamnosus GG (LGG) for rotavirus diarrhea have also been proposed in randomized 9 controlled studies (35) (36).
B) Inflammatory bowel diseases
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract. The most common types of IBD are ulcerative colitis (UC) and
Crohn's disease (CD), with the prevalence of IBD estimated to be 150,000 patients in Japan. Although the precise etiology of IBD is still obscure, the alterations in the intestinal microbiota are thought to play an important role in the pathogenesis of IBD.
Many trials were therefore conducted to manipulate the intestinal microflora using probiotics, including VSL#3, LGG, and E. coli Nissle 1917, and several potential therapeutic applications for UC have been conducted for the induction of remission and the relief of clinical symptoms (37) (38) (39) (40), maintenance of the clinical remission (41) (42), and prevention of the onset of pouchitis (43) (44) (45) (46) . Although controversial results have also been reported (47) , the administration of probiotics appears to be a promising modality for the treatment of UC. Conversely, the potential use of probiotics in the prevention or treatment of CD remains unclear. Several clinical studies have been performed to analyze the effects of probiotics on inducing clinical remission or maintaining surgically-induced remission using LGG or Lactobacillus johnsonii LA1. While one study found a modest reduction in the recurrence rates of patients after a surgical resection by supplementation with Lactobacillus johnsonii LA1, other studies revealed no benefit of probiotic administration for CD treatment ( Table 1 ).
The reason that no benefits were obtained by the administration of probiotics may be linked to a poor understanding of both the mechanisms of probiotics and the pathogenesis of CD. 
C) Irritable bowel disease

E) Antibiotic-associated enteritis
Antibiotic-associated enteritis is frequently observed in patients administered antibiotics, which can lead to the suppression of the normal gut microflora, thus causing a change in the gut microflora and the overgrowth of pathogenic bacteria. Typical antibiotics-associated enteritis includes acute hemorrhagic enteritis and pseudomembranous enterocolitis. Various meta-analyses have shown that probiotics successfully prevent antibiotic-associated enteritis (64) (65) (66). Probiotics aid the recovery of the gut microflora following antibiotic impairment. Antibiotics-associated enteritis is one of the diseases that benefit the most from probiotic treatment.
4) Extra-intestinal disorders A) Helicobacter pylori infection
Recent clinical trials revealed the beneficial effects of probiotics with antibiotic treatment for the eradication of Helicobactoer pylori (H. pylori) infection (67) (68) (69).
Almost all of the studies utilized Lactobacillae for these treatments. The mechanisms of H. pylori infection eradication were mediated by the antibiotic functions of lactic acid, bacteriocins, or other active components, competition for H. pylori adhesion to the gastric epithelia, enhancement of mucosal barrier function, and the modification of inflammatory mediators (70) (71) (72) (73) (74) (75) (76) (77) (78) (79). Probiotics can also relieve the side effects for the eradication of H. pylori infection (80) (81) (82) (83) (84) (85) (86) (87). However, no evidence has yet shown that probiotic treatment directly 
B) Others
It has also been reported that probiotic treatment is useful for curing urinary tract infections (91) and atopic diseases (92).
Mechanisms of probiotic functions
As mentioned in the previous section, probiotics are gaining widespread inclusion as a new preventive or therapeutic strategy for multiple gastrointestinal and extra-gastrointestinal diseases. However, these data are collected from an epidemiological analysis with the empirical selections of probiotics. In order to objectively determine how to choose the suitable strain for each disease, the mechanisms of probiotic functions must be clarified. In this regard, the mechanistic 14 analyses of probiotic functions for pathogenic bacteria as well as the host intestine are now under investigation (Figure 1 ).
1) Growth inhibition of pathogenic bacteria
Probiotics exhibit direct antibacterial effects for pathogenic bacteria through the production of antibacterial substances, including bacteriocins and acid (93) (94).
Gram-positive bacteria such as Lactococcus lactis produce small antimicrobial peptides, or lantibiotics (93) (95), which have been found to be an inhibitor for pathogenic bacteria by targeting the lipid II component of the bacterial cell wall (96) . Bacteriocins are other which was mediated by the activation of the p38-and JNK/MAPK pathway (116) . We have also demonstrated that Bacillus subtilis (B. subtilis) and its conditioned media induced Hsps in Caco-2/bbe cells and mouse intestine. In addition, we found that the B. subtilis-produced factor, competence and sporulation factor (CSF) mediates the Hsp induction and protective effect of B. subtilis against oxidant stress (117) , thus illustrating that the probiotic effects, at least in part, can be mediated by the induction of the cytoprotective Hsps. 
3) Inductions of cytoprotective heat shock proteins
4) Enhancement of intestinal barrier function
5) Modulations of host immune responses
Probiotics have the potential to modulate both innate and adaptive immunity.
Recent reports suggest that fecal sIgA is increased by Bifidobacterium animalis (123) Probiotics also exert an inhibitory effect on the production of pro-inflammatory
mediators. LGG or its conditioned media inhibits lipopolysaccharide-(LPS-) or
Helicobacter pylori-stimulated TNF production by murine macrophages (127) . E. coli Nissle 1917 suppresses TNF, IFN-γ, and IL-2 release, and increases IL-10 expression by T-cells (128) . L. casei Shirota decreases IL-6 and IFN-γ production induced by LPS in peripheral blood mononuclear cells of normal and colitis mice (129) . LGG and L.
rhamnosus GR-1 also induce granulocyte-colony stimulating factor (G-CSF) from macrophages, which inhibits E. coli-or LPS-induced TNF production (130) . On the other hand, it is proposed that VSL#3, E. coli Nissle 1917, Lactobacillus reuteri, and L. casei suppress excess inflammation through inducing IL-10 (128) (131) (132) (133) .
Conversely, probiotics enhance the host immune response when the host suffers from pathogenic bacteria infection. It is reported that dendritic cells take up a polysaccharide (PSA) of Bacteroides fragilis, which induces the maturation of dendritic cells and the production of Th1-type cytokines (134) . Therefore, probiotics regulate the host immune responses for each condition through the modulation of immune cells such as dendric cells, and by inducing production of pro-and anti-inflammatory factors.
NF-κB signaling is a pivotal pathway for epithelial interactions with immune cells. (142) . Conversely, the VSL#3 function for relieving mice colitis has also been reported to decrease in TLR9-deficient mice, but not in TLR2-or TLR4-knockout mice (143) , thus suggesting that specific TLRs are involved in the probiotic functions. However, the target PRR of each probiotic is unidentified, and it is unclear how TLRs distinguish the probiotic-derived molecules from those of pathogenic bacteria.
Our recent study shows that the B. subtilis-derived peptide CSF is imported by the epithelial cell membrane transporter protein (117) , a novel organic cation trasporter 2 (OCTN2), whose gene polymorphism is susceptible to Crohn's disease (144) . Furthermore, the protective effects of B. subtilis and its soluble factor CSF on the intestinal epithelia are reduced by inhibition of OCTN2 function (117) , suggesting that OCTN2 transport is essential for the effects of B. subtilis and CSF. This suggests a novel mechanism for sensing probiotics through the uptake of the soluble factors CSF, competence and sporulation factor; LPS, lipopolysaccharide; PG, peptidoglycan;
OCTN2, novel organic cation transporter 2; TLR, Toll-like receptor; MAPK, mitogen-activated protein kinase; TRAF6, TNF receptor-associated factor 6; Hsp, Heat 49 shock protein; NF-κB, nuclear factor-κB;
